Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle

Anwar Norazit1, Adrian C B Meedeniya, Maria Nga Nguyen

  • 1National Centre for Adult Stem Cell Research, Eskitis Institute, Griffith University, Brisbane, Queensland, Australia.

Brain Research
|September 3, 2010
PubMed

Insights

Low-dose rotenone infusion into the medial forebrain bundle induces oxidative stress and loss of dopaminergic neurons in rats. This provides a relevant animal model for Parkinson disease research.

Area of Science:

  • Neuroscience
  • Toxicology
  • Pathophysiology

Background:

  • Rotenone inhibits mitochondrial complex 1, leading to oxidative damage via reactive oxygen species.
  • Understanding rotenone's effects on the nigrostriatal pathway is crucial for modeling neurodegenerative diseases.

Purpose of the Study:

  • To investigate the pathophysiology of neuronal and glial cells in the nigrostriatal pathway after rotenone infusion.
  • To establish a relevant animal model for Parkinson disease.

Main Methods:

  • Unilateral infusion of varying rotenone doses into the substantia nigra or medial forebrain bundle of Sprague-Dawley rats.
  • Immunofluorescence techniques to assess dopaminergic neurons, glial cells, synapses, and oxidative stress markers at 14 and 60 days post-infusion.

Main Results:

  • Substantia nigra infusion caused extensive necrosis, limiting its use as a Parkinson disease model.
  • Medial forebrain bundle infusion (0.5μg rotenone) induced oxidative stress and loss of dopaminergic neurons and striatal fibers.
  • Increased astrocyte and microglial activation was observed in the substantia nigra.

Conclusions:

  • Low-dose rotenone targeting the medial forebrain bundle causes oxidative stress and progressive dopaminergic neurodegeneration.
  • This method provides a viable animal model for studying Parkinson disease pathophysiology and potential therapeutics.

Related Concept Videos

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.